Is Thermo Fisher (TMO) Using Cryo-EM And Olink To Redefine Its Drug Discovery Moat?

• Earlier this month, Thermo Fisher Scientific opened its Cryo-Electron Microscopy Drug Discovery Center in South San Francisco’s Oyster Point, giving pharmaceutical and biotech companies hands-on access to advanced cryo-EM technologies and scientific expertise to support faster structure-based drug discovery.
• The center, modeled on Thermo Fisher’s decade-long UK Pharmaceutical Cryo-EM Consortium, lowers adoption barriers and aims to deepen collaboration with founding customer members in North America while the company also advances its Olink acquisition to broaden endpoint solutions.
• Next, we’ll examine how the new cryo-EM center’s collaborative model could shape Thermo Fisher’s investment narrative and long-term tools positioning.

We’ve uncovered the 15 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.

Thermo Fisher Scientific Investment Narrative Recap

To own Thermo Fisher Scientific, you generally have to believe in its role as a critical tools and services provider across pharma, biotech, and diagnostics, with innovation helping offset funding and macro headwinds. The new cryo-EM Drug Discovery Center fits that thesis by reinforcing Thermo Fisher’s tools leadership and customer stickiness, but it does not materially change the near term focus on stabilizing demand in more pressured academic and government markets or the ongoing China and margin risks.

The opening of the South San Francisco cryo-EM center ties directly into Thermo Fisher’s push to deepen its pharma and biotech relationships, which CEO Marc Casper recently highlighted while discussing the company’s 3% to 4% growth target for 2026 and ongoing M&A plans, including the Olink acquisition. Together, these moves support the idea of Thermo Fisher as an end to end partner for drug discovery and development, even as external policy and funding risks remain in focus.

But even as the cryo EM center strengthens Thermo Fisher’s tools story, investors should be aware of rising tariff and China exposure risks that could…

Read the full narrative on Thermo Fisher Scientific (it’s free!)

Thermo Fisher Scientific’s narrative projects $50.0 billion revenue and $9.0 billion earnings by 2028. This requires 5.0% yearly revenue growth and a $2.4 billion earnings increase from $6.6 billion today.

Uncover how Thermo Fisher Scientific’s forecasts yield a $641.57 fair value, a 37% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already expecting about US$49.0 billion in revenue and US$8.4 billion in earnings by 2028, yet they worry that disruptive technologies and in house capabilities at big pharma could curb the benefit of new centers like this, so it is worth remembering that opinions differ widely and both bullish and bearish views may shift as investors reassess Thermo Fisher’s growth path in light of this development.

Explore 10 other fair value estimates on Thermo Fisher Scientific – why the stock might be worth 13% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

No Opportunity In Thermo Fisher Scientific?

The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com